Proteomics and metabolomics in biomarker discovery for cardiovascular diseases: progress and potential

References

• Tuñón J, Blanco-Colio L, Cristóbal C, et al. Usefulness of a combination of monocyte chemoattractant protein-1, galectin-3, and n-terminal probrain natriuretic peptide to predict cardiovascular events in patients with coronary artery disease. Am J Cardiol. 2014;113:434–440.
   PubMed Web of Science ®Google Scholar
• Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med. 2006;355:2631–2639.
   PubMed Web of Science ®Google Scholar
• Anderson L. Candidate-based proteomics in the search for biomarkers of cardiovascular disease. J Physiol. 2005;563(Pt 1):23–60.
   PubMed Web of Science ®Google Scholar
• Tuñón J, Martín-Ventura JL, Blanco-Colio LM, et al. Proteomic strategies in the search of new biomarkers in atherothrombosis. J Am Coll Cardiol. 2010;55:2009–2016.
   PubMed Web of Science ®Google Scholar
• Mann M, Hendrickson RC, Pandey A. Analysis of proteins and proteomes by mass spectrometry. Annu Rev Biochem. 2001;70:437–473.
   PubMed Web of Science ®Google Scholar
• Hu A, Noble W, Wolf-Yadlin A, Technical advances in proteomics: new developments in data-independent acquisition. F1000Research. 2016;5:419. [Version 1; referees: 3 approved].
   Google Scholar
• Senko MW, Remes PM, Canterbury JD, et al. Novel parallelized quadrupole/linear ion trap/orbitrap tribrid mass spectrometer improving proteome coverage and peptide identification rates. Anal Chem. 2013;85:11710–11714.
   PubMed Web of Science ®Google Scholar
• Archakov A, Zgoda V, Kopylov A, et al. Chromosome-centric approach to overcoming bottlenecks in the human proteome project. Expert Rev Proteomics. 2012;9:667–676.
   PubMed Web of Science ®Google Scholar
• Megger DA, Bracht T, Meyer HE, et al. Label-free quantification in clinical proteomics. Biochim Biophys Acta. 2013;1834:1581–1590.
   PubMed Web of Science ®Google Scholar
• Addona TA, Abbatiello SE, Schilling B, et al. Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotech. 2009;27:633–641.
   PubMed Web of Science ®Google Scholar
• Martínez-Aguilar J, Clifton-Bligh R, Molloy MP. A multiplexed, targeted mass spectrometry assay of the S100 protein family uncovers the isoform-specific expression in thyroid tumours. BMC Cancer. 2015;15:199.
   PubMed Web of Science ®Google Scholar
• Gianazza E, Tremoli E, Banfi C. The selected reaction monitoring/multiple reaction monitoring-based mass spectrometry approach for the accurate quantitation of proteins: clinical applications in the cardiovascular diseases. Expert Rev Proteomics. 2014;11:771–788.
   PubMed Web of Science ®Google Scholar
• Khristenko N, Domon B. Quantification of proteins in urine samples using targeted mass spectrometry methods. In: Vlahou A, Makridakis M, editors. Clinical proteomics: methods and protocols. New York (NY): Springer New York; 2015. p. 207–220.
   Google Scholar
• Peterson AC, Russell JD, Bailey DJ, et al. Parallel reaction monitoring for high resolution and high mass accuracy quantitative, targeted proteomics. MCP. 2012;11:1475–1488.
   Web of Science ®Google Scholar
• Carr SA, Abbatiello SE, Ackermann BL, et al. Targeted peptide measurements in biology and medicine: best practices for mass spectrometry-based assay development using a fit-for-purpose approach. Mol Cell Proteomics. 2014;13:907–917.
   PubMed Web of Science ®Google Scholar
• Venable JD, Dong M-Q, Wohlschlegel J, et al. Automated approach for quantitative analysis of complex peptide mixtures from tandem mass spectra. Nat Methods. 2004;1:39–45.
   PubMed Web of Science ®Google Scholar
• Chapman JD, Goodlett DR, Masselon CD. Multiplexed and data-independent tandem mass spectrometry for global proteome profiling. Mass Spectrom Rev. 2014;33:452–470.
   PubMed Web of Science ®Google Scholar
• Fach EM, Garulacan L-A, Gao J, et al. In vitro biomarker discovery for atherosclerosis by proteomics. Mol Cell Proteomics. 2004;3:1200–1210.
   PubMed Web of Science ®Google Scholar
• Coppinger JA, Cagney G, Toomey S, et al. Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood. 2003;103:2096–2104.
   PubMed Web of Science ®Google Scholar
• De Kleijn DPV, Moll FL, Hellings WE, et al. Local atherosclerotic plaques are a source of prognostic biomarkers for adverse cardiovascular events. Arterioscler Thromb Vasc Biol. 2010;30:612–619.
   PubMed Web of Science ®Google Scholar
• Mas S, Touboul D, Brunelle A, et al. Lipid cartography of atherosclerotic plaque by cluster-TOF-SIMS imaging. Analyst. 2007;132:24–26.
   PubMed Web of Science ®Google Scholar
• Duran MC, Mas S, Martin-Ventura JL, et al. Proteomic analysis of human vessels: application to atherosclerotic plaques. Proteomics. 2003;3:973–978.
   PubMed Web of Science ®Google Scholar
• Martin-Ventura JL, Duran MC, Blanco-Colio LM, et al. Identification by a differential proteomic approach of heat shock protein 27 as a potential marker of atherosclerosis. Circulation. 2004;110:2216–2219.
   PubMed Web of Science ®Google Scholar
• Durán MC, Martín-Ventura JL, Mohammed S, et al. Atorvastatin modulates the profile of proteins released by human atherosclerotic plaques. Eur J Pharmacol. 2007;562(1–2):119–129.
   PubMed Web of Science ®Google Scholar
• Martinez-Pinna R, Ramos-Mozo P, Madrigal-Matute J, et al. Identification of peroxiredoxin-1 as a novel biomarker of abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol. 2011;31:935–943.
   PubMed Web of Science ®Google Scholar
• Martinez-Pinna R, Madrigal-Matute J, Tarin C, et al. Proteomic analysis of intraluminal thrombus highlights complement activation in human abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2013;33:2013–2020.
   PubMed Web of Science ®Google Scholar
• Barderas MG, Tuñón J, Dardé VM, et al. Circulating human monocytes in the acute coronary syndrome express a characteristic proteomic profile. J Proteome Res. 2007;6:876–886.
   PubMed Web of Science ®Google Scholar
• Barderas MG, Tuñón J, Dardé VM, et al. Atorvastatin modifies the protein profile of circulating human monocytes after an acute coronary syndrome. Proteomics. 2009;9:1982–1993.
   PubMed Web of Science ®Google Scholar
• Tan S-H, Mohamedali A, Kapur A, et al. Ultradepletion of human plasma using chicken antibodies: a proof of concept study. J Proteome Res. 2013;12:2399–2413.
   PubMed Web of Science ®Google Scholar
• Gordon SM, Deng J, Tomann AB, et al. Multi-dimensional co-separation analysis reveals protein-protein interactions defining plasma lipoprotein subspecies. Mol Cell Proteomics. 2013;12:3123–3134.
   PubMed Web of Science ®Google Scholar
• Favari E, Chroni A, Tietge UJ, et al. Cholesterol efflux and reverse cholesterol transport. Handb Exp Pharmacol. 2015;224:181–206.
   PubMedGoogle Scholar
• Murphy AJ, Woollard KJ. High-density lipoprotein: a potent inhibitor of inflammation. Clin Exp Pharmacol Physiol. 2010;37:710–718.
   PubMed Web of Science ®Google Scholar
• Stoep M, Korporaal SJ, Van Eck M. High-density lipoprotein as a modulator of platelet and coagulation responses. Cardiovasc Res. 2014;103:362–371.
   PubMed Web of Science ®Google Scholar
• Gordon D, Probstfield J, Garrison R, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective american studies. Circulation. 1989;79:8–15.
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367:2089–2099.
   PubMed Web of Science ®Google Scholar
• Burillo E, Andres EM, Mateo-Gallego R, et al. High-density lipoprotein cholesterol increase and non-cardiovascular mortality: a meta-analysis. Heart. 2010;96:1345–1351.
   PubMed Web of Science ®Google Scholar
• Yamamoto S, Yancey PG, Ikizler TA, et al. Dysfunctional high-density lipoprotein in patients on chronic hemodialysis. J Am Coll Cardiol. 2012;60:2372–2379.
   PubMed Web of Science ®Google Scholar
• Rabilloud T, Lelong C. Two-dimensional gel electrophoresis in proteomics: a tutorial. J Proteomics. 2011;74:1829–1841.
   PubMed Web of Science ®Google Scholar
• Altelaar AF, Munoz J, Heck AJ. Next-generation proteomics: towards an integrative view of proteome dynamics. Nat Rev Genet. 2013;14:35–48.
   PubMed Web of Science ®Google Scholar
• Heller M, Stalder D, Schlappritzi E, et al. Mass spectrometry-based analytical tools for the molecular protein characterization of human plasma lipoproteins. Proteomics. 2005;5:2619–2630.
   PubMed Web of Science ®Google Scholar
• Catapano AL, Pirillo A, Bonacina F, et al. HDL in innate and adaptive immunity. Cardiovasc Res. 2014;103:372–383.
   PubMed Web of Science ®Google Scholar
• Vaisar T, Pennathur S, Green PS, et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest. 2007;117:746–756.
   PubMed Web of Science ®Google Scholar
• Heinecke JW. The protein cargo of HDL: implications for vascular wall biology and therapeutics. J Clin Lipidol. 2010;4:371–375.
   PubMed Web of Science ®Google Scholar
• Vaisar T. Proteomics investigations of HDL: challenges and promise. Curr Vasc Pharmacol. 2012;10:410–421.
   PubMed Web of Science ®Google Scholar
• Jorge I, Burillo E, Mesa R, et al. The human HDL proteome displays high inter-individual variability and is altered dynamically in response to angioplasty-induced atheroma plaque rupture. J Proteomics. 2014;106:61–73.
   PubMed Web of Science ®Google Scholar
• Alwaili K, Bailey D, Awan Z, et al. The HDL proteome in acute coronary syndromes shifts to an inflammatory profile. Biochim Biophys Acta. 2012;1821:405–415.
   PubMed Web of Science ®Google Scholar
• Tan Y, Liu TR, Hu SW, et al. Acute coronary syndrome remodels the protein cargo and functions of high-density lipoprotein subfractions. PLoS One. 2014;9:e94264.
   PubMed Web of Science ®Google Scholar
• Yan L-R, Wang D-X, Liu H,, . A pro-atherogenic HDL profile in coronary heart disease patients: an iTRAQ labelling-based proteomic approach. PLoS One. 2014;9:e98368.
   PubMed Web of Science ®Google Scholar
• Yassine HN, Jackson AM, Reaven PD, et al. The application of multiple reaction monitoring to assess Apo A-I methionine oxidations in diabetes and cardiovascular disease. Transl Proteom. 2014;4–5:18–24.
   PubMedGoogle Scholar
• Marsillach J, Becker JO, Vaisar T, et al. Paraoxonase-3 is depleted from the high-density lipoproteins of autoimmune disease patients with subclinical atherosclerosis. J Proteome Res. 2015;14:2046–2054.
   PubMed Web of Science ®Google Scholar
• Loyer X, Vion A-C, Tedgui A, et al. Microvesicles as cell-cell messengers in cardiovascular diseases. Circ Res. 2014;114:345–353.
   PubMed Web of Science ®Google Scholar
• Palmisano G, Jensen SS, Le Bihan M-C, et al. Characterization of membrane-shed microvesicles from cytokine-stimulated β-cells using proteomics strategies. Mol Cell Proteomics. 2012;11:230–243.
   PubMed Web of Science ®Google Scholar
• Burnier L, Fontana P, Kwak BR, et al. Cell-derived microparticles in haemostasis and vascular medicine. Thromb Haemost. 2009;101:439–451.
   PubMed Web of Science ®Google Scholar
• Hoefer IE, Steffens S, Ala-Korpela M, et al. Novel methodologies for biomarker discovery in atherosclerosis. Eur Heart J. 2015;36:2635–2642.
   PubMed Web of Science ®Google Scholar
• Kapustin AN, Shanahan CM. Emerging roles for vascular smooth muscle cell exosomes in calcification and coagulation. J Physiol. 2016 Feb 10;594:2905–2914. Epub ahead of print. doi:10.1113/JP271340.
   PubMed Web of Science ®Google Scholar
• Huber HJ, Holvoet P. Exosomes: emerging roles in communication between blood cells and vascular tissues during atherosclerosis. Curr Opin Lipidol. 2015;26:412–419.
   PubMed Web of Science ®Google Scholar
• Yuan M-J, Maghsoudi T, Wang T. Exosomes mediate the intercellular communication after myocardial infarction. Int J Med Sci. 2016;13:113–116.
   PubMed Web of Science ®Google Scholar
• Mayr M, Grainger D, Mayr U, et al. Proteomics, metabolomics, and immunomics on microparticles derived from human atherosclerotic plaques. Circ Cardiovasc Genet. 2009;2:379–388.
   PubMed Web of Science ®Google Scholar
• Lal S, Brown A, Nguyen L, et al. Using antibody arrays to detect microparticles from acute coronary syndrome patients based on cluster of differentiation (CD) antigen expression. Mol Cell Proteomics. 2009;8:799–804.
   PubMed Web of Science ®Google Scholar
• Martinez-Pinna R, Gonzalez de Peredo A, Monsarrat B, et al. Label-free quantitative proteomic analysis of human plasma-derived microvesicles to find protein signatures of abdominal aortic aneurysms. Proteomics Clin Appl. 2014;8:620–625.
   PubMed Web of Science ®Google Scholar
• Willms E, Johansson HJ, Mäger I, et al. Cells release subpopulations of exosomes with distinct molecular and biological properties. Sci Rep. 2016;6:22519.
   PubMed Web of Science ®Google Scholar
• Goetzl EJ, Goetzl L, Karliner JS, et al. Human plasma platelet-derived exosomes: effects of aspirin. FASEB J. 2016;30:2058–2063.
   PubMed Web of Science ®Google Scholar
• Yin M, Loyer X, Boulanger CM. Extracellular vesicles as new pharmacological targets to treat atherosclerosis. Eur J Pharmacol. 2015;763(Pt A):90–103.
   PubMed Web of Science ®Google Scholar
• Blanco-Colio LM, Martín-Ventura JL, Muñóz-García B, et al. Identification of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis. Arterioscler Thromb Vasc Biol. 2007;27:916–922.
   PubMed Web of Science ®Google Scholar
• Chicheportiche Y, Bourdon PR, Xu H, et al. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem. 1997;272:32401–32410.
   PubMed Web of Science ®Google Scholar
• Kralisch S, Ziegelmeier M, Bachmann A, et al. Serum levels of the atherosclerosis biomarker sTWEAK are decreased in type 2 diabetes and end-stage renal disease. Atherosclerosis. 2008;199:440–444.
   PubMed Web of Science ®Google Scholar
• Fernández-Laso V, Sastre C, Valdivielso JM, et al. Soluble TWEAK levels predict the presence of carotid atherosclerotic plaques in subjects free from clinical cardiovascular diseases. Atherosclerosis. 2015;239:358–363.
   PubMed Web of Science ®Google Scholar
• Moreno JA, Dejouvencel T, Labreuche J, et al. Peripheral artery disease is associated with a high CD163/TWEAK plasma ratio. Arterioscler Thromb Vasc Biol. 2010;30:1253–1262.
   PubMed Web of Science ®Google Scholar
• Jelić-Ivanović Z, Bujisić N, Spasić S, et al. Circulating sTWEAK improves the prediction of coronary artery disease. Clin Biochem. 2009;42:1381–1386.
   PubMed Web of Science ®Google Scholar
• Martín-Ventura JL, Lindholt JS, Moreno JA, et al. Soluble TWEAK plasma levels predict expansion of human abdominal aortic aneurysms. Atherosclerosis. 2011;214:486–489.
   PubMed Web of Science ®Google Scholar
• Chorianopoulos E, Rosenberg M, Zugck C, et al. Decreased soluble TWEAK levels predict an adverse prognosis in patients with chronic stable heart failure. Eur J Heart Fail. 2009;11:1050–1056.
   PubMed Web of Science ®Google Scholar
• Valdivielso JM, Coll B, Martín-Ventura JL, et al. Soluble TWEAK is associated with atherosclerotic burden in patients with chronic kidney disease. J Nephrol. 2013;26:1105–1113.
   PubMed Web of Science ®Google Scholar
• Simon A, Megnien J-L, Chironi G. The value of carotid intima-media thickness for predicting cardiovascular risk. Arterioscler Thromb Vasc Biol. 2010;30:182–185.
   PubMed Web of Science ®Google Scholar
• Yilmaz MI, Sonmez A, Ortiz A, et al. Soluble TWEAK and PTX3 in nondialysis CKD patients: impact on endothelial dysfunction and cardiovascular outcomes. Clin J Am Soc Nephrol. 2011;6:785–792.
   PubMed Web of Science ®Google Scholar
• Hassan SB, El-demery AB, Ahmed AI, et al. Soluble TWEAK and cardiovascular morbidity and mortality in chronic kidney disease patients. Arab J Nephrol Transplant. 2012;5:27–32.
   PubMedGoogle Scholar
• Flammer AJ, Anderson T, Celermajer DS, et al. The assessment of endothelial function: from research into clinical practice. Circulation. 2012;126:753–767.
   PubMed Web of Science ®Google Scholar
• Yilmaz MI, Carrero JJ, Ortiz A, et al. Soluble TWEAK plasma levels as a novel biomarker of endothelial function in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2009;4:1716–1723.
   PubMed Web of Science ®Google Scholar
• Yilmaz MI, Carrero JJ, Martín-Ventura JL, et al. Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation. Clin J Am Soc Nephrol. 2010;5:1174–1181.
   PubMed Web of Science ®Google Scholar
• Urbonaviciene G, Martin-Ventura JL, Lindholt JS, et al. Impact of soluble TWEAK and CD163/TWEAK ratio on long-term cardiovascular mortality in patients with peripheral arterial disease. Atherosclerosis. 2011;219:892–899.
   PubMed Web of Science ®Google Scholar
• Fernández-Laso V, Sastre C, Valdivielso JM, et al. Soluble TWEAK and major adverse cardiovascular events in patients with CKD. Clin J Am Soc Nephrol. 2016;11:413–422.
   PubMed Web of Science ®Google Scholar
• Richter B, Rychli K, Hohensinner PJ, et al. Differences in the predictive value of tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in advanced ischemic and non-ischemic heart failure. Atherosclerosis. 2010;213:545–548.
   PubMed Web of Science ®Google Scholar
• Muñoz-García B, Martín-Ventura JL, Martínez E, et al. Fn14 is upregulated in cytokine-stimulated vascular smooth muscle cells and is expressed in human carotid atherosclerotic plaques: modulation by atorvastatin. Stroke. 2006;37:2044–2053.
   PubMed Web of Science ®Google Scholar
• Bover LC, Cardó-Vila M, Kuniyasu A, et al. A previously unrecognized protein-protein interaction between TWEAK and CD163: potential biological implications. J Immunol. 2007;178:8183–8194.
   PubMed Web of Science ®Google Scholar
• Shen X, Zheng S, Thongboonkerd V, et al. Cardiac mitochondrial damage and biogenesis in a chronic model of type 1 diabetes. Am J Physiol. 2004;287:E896–E905.
   Web of Science ®Google Scholar
• Johnson DT, Harris RA, French S, et al. Proteomic changes associated with diabetes in the BB-DP rat. Am J Physiol. 2009;296:E422–E432.
   Web of Science ®Google Scholar
• Dekkers DHW, Bezstarosti K, Gurusamy N, et al. Identification by a differential proteomic approach of the induced stress and redox proteins by resveratrol in the normal and diabetic rat heart. J Cell Mol Med. 2008;12:1677–1689.
   PubMed Web of Science ®Google Scholar
• Baseler WA, Dabkowski ER, Williamson CL, et al. Proteomic alterations of distinct mitochondrial subpopulations in the type 1 diabetic heart: contribution of protein import dysfunction. Am J Physiol. 2011;300:R186–R200.
   PubMed Web of Science ®Google Scholar
• Baseler WA, Dabkowski ER, Jagannathan R, et al. Reversal of mitochondrial proteomic loss in Type 1 diabetic heart with overexpression of phospholipid hydroperoxide glutathione peroxidase. Am J Physiol. 2013;304:R553–R565.
   PubMed Web of Science ®Google Scholar
• Jüllig M, Chen X, Hickey AJ, et al. Reversal of diabetes-evoked changes in mitochondrial protein expression of cardiac left ventricle by treatment with a copper(II)-selective chelator. Proteomics Clin Appl. 2007;1:387–399.
   PubMed Web of Science ®Google Scholar
• Yu Q, Liu B, Ruan D, et al. A novel targeted proteomics method for identification and relative quantitation of difference in nitration degree of OGDH between healthy and diabetic mouse. Proteomics. 2014;14:2417–2426.
   PubMed Web of Science ®Google Scholar
• Karthik D, Vijayakumar R, Pazhanichamy K, et al. A proteomics approach to identify the differential protein level in cardiac muscle of diabetic rat. Acta Biochim Pol. 2014;61:285–293.
   PubMed Web of Science ®Google Scholar
• Dewey S, Lai X, Witzmann FA, et al. Proteomic analysis of hearts from akita mice suggests that increases in soluble epoxide hydrolase and antioxidative programming are key changes in early stages of diabetic cardiomyopathy. J Proteome Res. 2013;12:3920–3933.
   PubMed Web of Science ®Google Scholar
• Boudina S, Bugger H, Sena S, et al. Contribution of impaired myocardial insulin signaling to mitochondrial dysfunction and oxidative stress in the heart. Circulation. 2009;119:1272–1283.
   PubMed Web of Science ®Google Scholar
• Bugger H, Riehle C, Jaishy B, et al. Genetic loss of insulin receptors worsens cardiac efficiency in diabetes. J Mol Cell Cardiol. 2012;52:1019–1026.
   PubMed Web of Science ®Google Scholar
• Ares-Carrasco S, Picatoste B, Camafeita E, et al. Proteome changes in the myocardium of experimental chronic diabetes and hypertension: role of PPARα in the associated hypertrophy. J Proteomics. 2012;75:1816–1829.
   PubMed Web of Science ®Google Scholar
• Cruz-Topete D, List EO, Okada S, et al. Proteomic changes in the heart of diet-induced pre-diabetic mice. J Proteomics. 2011;74:716–727.
   PubMed Web of Science ®Google Scholar
• Littlejohns B, Pasdois P, Duggan S, et al. Hearts from mice fed a non-obesogenic high-fat diet exhibit changes in their oxidative state, calcium and mitochondria in parallel with increased susceptibility to reperfusion injury. PLoS One. 2014;9:e100579.
   PubMed Web of Science ®Google Scholar
• Essop MF, Chan WA, Hattingh S. Proteomic analysis of mitochondrial proteins in a mouse model of type 2 diabetes. Cardiovasc J Afr. 2010;22:175–178.
   PubMed Web of Science ®Google Scholar
• Das A, Durrant D, Koka S, et al. Mammalian target of rapamycin (mTOR) inhibition with rapamycin improves cardiac function in type 2 diabetic mice: potential role of attenuated oxidative stress and altered contractile protein expression. J Biol Chem. 2014;289:4145–4160.
   PubMed Web of Science ®Google Scholar
• Cai Q, Li B, Yu F, et al. Investigation of the protective effects of phlorizin on diabetic cardiomyopathy in db/db mice by quantitative proteomics. J Diabetes Res. 2013;2013:9.
   Web of Science ®Google Scholar
• Koka S, Xi L, Kukreja RC. Chronic treatment with long acting phosphodiesterase-5 inhibitor tadalafil alters proteomic changes associated with cytoskeletal rearrangement and redox regulation in Type 2 diabetic hearts. Basic Res Cardiol. 2012;107:1–14.
   Web of Science ®Google Scholar
• Luan S-S, Yu F, Li B-Y, et al. Quantitative proteomics study of protective effects of grape seed procyanidin B2 on diabetic cardiomyopathy in db/db mice. Biosci Biotechnol Biochem. 2014;78:1577–1583.
   PubMed Web of Science ®Google Scholar
• Rindler PM, Plafker SM, Szweda LI, et al. High dietary fat selectively increases catalase expression within cardiac mitochondria. J Biol Chem. 2013;288:1979–1990.
   PubMed Web of Science ®Google Scholar
• Meierhofer D, Weidner C, Hartmann L, et al. Protein sets define disease states and predict in vivo effects of drug treatment. Mol Cell Proteomics. 2013;12:1965–1979.
   PubMed Web of Science ®Google Scholar
• Ljunggren SA, Iggland M, Rönn M, et al. Altered heart proteome in fructose-fed Fisher 344 rats exposed to bisphenol A. Toxicology. 2016;347–349:6–16.
   PubMed Web of Science ®Google Scholar
• Lewis GD, Asnani A, Gerszten RE. Application of metabolomics to cardiovascular biomarker and pathway discovery. J Am Coll Cardiol. 2008;52:117–2.
   PubMed Web of Science ®Google Scholar
• Rhee EP, Gerszten RE. Metabolomics and cardiovascular biomarker discovery. Clin Chem. 2012;58:139–147.
   PubMed Web of Science ®Google Scholar
• Heather LC, Wang X, West JA, et al. A practical guide to metabolomic profiling as a discovery tool for human heart disease. J Mol Cell Cardiol. 2013;55:2–11.
   PubMed Web of Science ®Google Scholar
• Senn T, Hazen SL, Tang WHW. Translating metabolomics to cardiovascular biomarkers. Progr Cardiovasc Dis. 2012;55:70–76.
   PubMed Web of Science ®Google Scholar
• Alawieh A, Kobaissy HF, Kurban M, et al. Metabolomics in cardiovascular diseases: biomarkers quest. Data Mining Genomics Proteomics. 2013;S2:e001. doi:10.4172/2153-0602.S2-e001.
   Google Scholar
• Shah SH, Kraus WE, Newgard CB. Metabolomic profiling for the identification of novel biomarkers and mechanisms related to common cardiovascular diseases: form and function. Circulation. 2012;126:1110–1120.
   PubMed Web of Science ®Google Scholar
• Vaarhorst AAM, Verhoeven A, Weller CM, et al. A metabolomic profile is associated with the risk of incident coronary heart disease. Am Heart J. 2014;168:45–52.e7.
   PubMed Web of Science ®Google Scholar
• Rizza S, Copetti M, Rossi C, et al. Metabolomics signature improves the prediction of cardiovascular events in elderly subjects. Atherosclerosis. 2014;232:260–264.
   PubMed Web of Science ®Google Scholar
• Cheng M-L, Wang C-H, Shiao M-S, et al. Metabolic disturbances identified in plasma are associated with outcomes in patients with heart failure: diagnostic and prognostic value of metabolomics. J Am Coll Cardiol. 2015;65:1509–1520.
   PubMed Web of Science ®Google Scholar
• Teul J, Rupérez FJ, Garcia A, et al. Improving metabolite knowledge in stable atherosclerosis patients by association and correlation of GC-MS and 1H NMR fingerprints. J Proteome Res. 2009;8:5580–5589.
   PubMed Web of Science ®Google Scholar
• Turer AT, Stevens RD, Bain JR, et al. Metabolomic profiling reveals distinct patterns of myocardial substrate use in humans with coronary artery disease or left ventricular dysfunction during surgical ischemia/reperfusion. Circulation. 2009;119:1736–1746.
   PubMed Web of Science ®Google Scholar
• Lin H, Zhang J, Gao P. Silent myocardial ischemia is associated with altered plasma phospholipids. J Clin Lab Anal. 2009;23:45–50.
   PubMed Web of Science ®Google Scholar
• Würtz P, Havulinna AS, Soininen P, et al. Metabolite profiling and cardiovascular event risk. Circulation. 2015;131:774–785.
   PubMed Web of Science ®Google Scholar
• Vorkas PA, Isaac G, Anwar MA, et al. Untargeted UPLC-MS profiling pipeline to expand tissue metabolome coverage: application to cardiovascular disease. Anal Chem. 2015;87:4184–4193.
   PubMed Web of Science ®Google Scholar
• Shah SH, Bain JR, Muehlbauer MJ, et al. Association of a peripheral blood metabolic profile with coronary artery disease and risk of subsequent cardiovascular events. Circulation. 2010;3:207–214.
   PubMed Web of Science ®Google Scholar
• Shah SH, Sun J-L, Stevens RD, et al. Baseline metabolomic profiles predict cardiovascular events in patients at risk for coronary artery disease. Am Heart J. 2012;163:844–850.e1.
   PubMed Web of Science ®Google Scholar
• Hattori K, Kajimura M, Hishiki T, et al. Paradoxical ATP elevation in ischemic penumbra revealed by quantitative imaging mass spectrometry. Antioxid Redox Signal. 2010;13:1157–1167.
   PubMed Web of Science ®Google Scholar
• Kang S-M, Park J-C, Shin M-J, et al. 1H nuclear magnetic resonance based metabolic urinary profiling of patients with ischemic heart failure. Clin Biochem. 2011;44:293–299.
   PubMed Web of Science ®Google Scholar
• Lewis GD, Wei R, Liu E, et al. Metabolite profiling of blood from individuals undergoing planned myocardial infarction reveals early markers of myocardial injury. J Clin Invest. 2008;118:3503–3512.
   PubMed Web of Science ®Google Scholar
• Kimura T, Noguchi Y, Shikata N, et al. Plasma amino acid analysis for diagnosis and amino acid-based metabolic networks. Curr Opin Clin Nutr Metab Care. 2009;12:49–53.
   PubMed Web of Science ®Google Scholar
• Davis B, Koster G, Douet LJ, et al. Electrospray ionization mass spectrometry identifies substrates and products of lipoprotein-associated phospholipase A2 in oxidized human low density lipoprotein. J Biol Chem. 2008;283:6428–6437.
   PubMed Web of Science ®Google Scholar